Literature DB >> 21143281

Physiological actions of angiotensin II mediated by AT1 AND AT2 receptors in the brain.

M J McKinley1, R M McAllen, G L Pennington, A Smardencas, R S Weisinger, B J Oldfield.   

Abstract

1. Autoradiographic binding studies have shown that the AT(1) receptor is the predominant angiotensin II (AngII) receptor subtype in the central nervous system (CNS). Major sites of AT(1) receptors are the lamina terminalis, hypothalamic paraventricular nucleus, the lateral parabrachial nucleus, rostral and caudal ventrolateral medulla, nucleus of the solitary tract and the intermediolateral cell column of the thoraco-lumbar spinal cord. 2. While there are differences between species, AT(2) receptors are found mainly in the cerebellum, inferior olive and locus coeruleus of the rat. 3. Circulating AngII acts on AT(1) receptors in the subfornical organ and organum vasculosum of the lamina terminalis (OVLT) to stimulate neurons that may have a role in initiating water drinking. 4. Centrally administered AngII may act on AT(1) receptors in the median preoptic nucleus and elsewhere to induce drinking, sodium appetite, a sympathetic vasoconstrictor response and vasopressin secretion. 5. Recent evidence shows that centrally administered AT(1) antagonists inhibit dipsogenic, natriuretic, pressor and vasopressin secretory responses to intracerebroventricular infusion of hypertonic saline. This suggests that an angiotensinergic neural pathway has a role in osmoregulatory responses. 6. Central angiotensinergic pathways which include neural inputs to the rostral ventrolateral medulla may use AT(1) receptors and play a role in the function of sympathetic pathways maintaining arterial pressure. 1996 Blackwell Publishing Asia Pty Ltd.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 21143281     DOI: 10.1111/j.1440-1681.1996.tb02821.x

Source DB:  PubMed          Journal:  Clin Exp Pharmacol Physiol        ISSN: 0305-1870            Impact factor:   2.557


  7 in total

1.  Angiotensin AT1A receptors expressed in vasopressin-producing cells of the supraoptic nucleus contribute to osmotic control of vasopressin.

Authors:  Jeremy A Sandgren; Danny W Linggonegoro; Shao Yang Zhang; Sarah A Sapouckey; Kristin E Claflin; Nicole A Pearson; Mariah R Leidinger; Gary L Pierce; Mark K Santillan; Katherine N Gibson-Corley; Curt D Sigmund; Justin L Grobe
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2018-01-24       Impact factor: 3.619

2.  A novel regulator of thirst behavior: phoenixin.

Authors:  Christopher J Haddock; Gislaine Almeida-Pereira; Lauren M Stein; Gina L C Yosten; Willis K Samson
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2020-04-15       Impact factor: 3.619

3.  Differential effects of prenatal exposure to dexamethasone or cortisol on circulatory control mechanisms mediated by angiotensin II in the central nervous system of adult sheep.

Authors:  M Dodic; A T McAlinden; A J Jefferies; E M Wintour; M L Cock; C N May; R G Evans; K M Moritz
Journal:  J Physiol       Date:  2006-01-19       Impact factor: 5.182

4.  A peripherally administered, centrally acting angiotensin II AT2 antagonist selectively increases brain AT1 receptors and decreases brain tyrosine hydroxylase transcription, pituitary vasopressin and ACTH.

Authors:  Miroslava Macova; Jaroslav Pavel; Juan M Saavedra
Journal:  Brain Res       Date:  2008-11-12       Impact factor: 3.252

Review 5.  Compromised blood-brain barrier permeability: novel mechanism by which circulating angiotensin II signals to sympathoexcitatory centres during hypertension.

Authors:  V C Biancardi; J E Stern
Journal:  J Physiol       Date:  2015-12-21       Impact factor: 5.182

6.  Chiropractic care for hypertension: Review of the literature and study of biological and genetic bases.

Authors:  Stephanie Gb Sullivan; Stefano Paolacci; Aysha Karim Kiani; Matteo Bertelli
Journal:  Acta Biomed       Date:  2020-11-09

Review 7.  Anthracycline-induced cardiotoxicity and renin-angiotensin-aldosterone system-from molecular mechanisms to therapeutic applications.

Authors:  Paweł Sobczuk; Magdalena Czerwińska; Marcin Kleibert; Agnieszka Cudnoch-Jędrzejewska
Journal:  Heart Fail Rev       Date:  2022-01       Impact factor: 4.214

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.